3 results
The primary objective is to evaluate the efficacy and safety of NTRA-9620 compared with placebo when added to standard of care (SOC) in pediatric subjects (aged 28 weeks post-menstrual age to 52 weeks chronological age) with SBS within 4 months from…
Primary:* Phase I: to establish the recommended phase II dose (RP2D) of BCT-100 in children andyoung adults as assessed by dose limiting toxicity (DLT) and complete arginine depletion.* Phase II: to determine the activity of single agent BCT-100…
Primary Objective• Evaluate the efficacy of loncastuximab tesirine combined with rituximab compared to standard immunochemotherapy Secondary Objectives• Further evaluate the efficacy of loncastuximab tesirine combined with rituximab compared to…